Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 19/20 | 0.49 |
| ▸ | EGFR | P00533 | 3/20 | 0.49 |
| ▸ | ABL1 | P00519 | 2/20 | 0.46 |
| ▸ | ABL2 | P42684 | 2/20 | 0.46 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23854965 | 1.00 | SRC (0.49) | SRCEGFRABL1ABL2MAP4K4 | |
| SCHEMBL23854967 | 1.00 | SRC (0.49) | SRCEGFRABL1ABL2MAP4K4 | |
| SCHEMBL30054387 | 1.00 | SRC (0.49) | SRCEGFRABL1ABL2MAP4K4 | |
| SCHEMBL23834479 | 0.84 | SRC (0.53) | SRCEGFRABL1MAP4K4 | |
| SCHEMBL30055248 | 0.84 | SRC (0.53) | SRCEGFRABL1MAP4K4 | |
| SCHEMBL23834569 | 0.84 | SRC (0.53) | SRCEGFRABL1MAP4K4 | |
| SCHEMBL30056804 | 0.84 | SRC (0.53) | SRCEGFRABL1MAP4K4 | |
| SCHEMBL31463180 | 0.83 | SRC (0.58) | SRCEGFRABL1ABL2 | |
| SCHEMBL30035929 | 0.83 | SRC (0.58) | SRCEGFRABL1ABL2 | |
| SCHEMBL1444035 | 0.82 | SRC (0.64) | SRCEGFRABL1ABL2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11963960-B2 | Compounds for treating or inhibiting recurrence of acute myeloid leukemia | FLASH THERAPEUTICS, LLC (US) | 2024-04-23 | — | — | US | disclosed |
| EP-4121430-A1 | COMPOUNDS FOR TREATING OR INHIBITING RECURRENCE OF ACUTE MYELOID LEUKEMIA | Flash Therapeuttics, LLC (US) | 2023-01-25 | — | — | EP | disclosed |
| CN-115298180-A | Compounds for treating or inhibiting recurrence of acute myeloid leukemia | 富雷旭医疗有限责任公司 | 2022-11-04 | — | — | CN | disclosed |
| US-20210299128-A1 | COMPOUNDS FOR TREATING OR INHIBITING RECURRENCE OF ACUTE MYELOID LEUKEMIA | RIKEN (JP) | 2021-09-30 | — | — | US | disclosed |
| US-20210299128-A1 | COMPOUNDS FOR TREATING OR INHIBITING RECURRENCE OF ACUTE MYELOID LEUKEMIA | RIKEN (JP) | 2021-09-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11963960-B2 | Compounds for treating or inhibiting recurrence of acute myeloid leukemia | MCL1, FLT3, ABL1 | SRC 95/4885EGFR 231/4885ABL1 3/4885 |
| US-20210299128-A1 | COMPOUNDS FOR TREATING OR INHIBITING RECURRENCE OF ACUTE MYELOID LEUKEMIA | MCL1, FLT3, ABL1 | SRC 95/4885EGFR 231/4885ABL1 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.